The γ-Hydroxybutyrate withdrawal syndrome

Toxicological Reviews

Volumn 23, Issue 1, 2004, Pages 45-49

  Tarabar, Asim F ^a,b   Nelson, Lewis S ^a  

^a NEW YORK CITY POISON CONTROL CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYBUTYRIC ACID; BENZODIAZEPINE DERIVATIVE; GAMMA BUTYROLACTONE; HYPNOTIC SEDATIVE AGENT; OXYBATE SODIUM; PENTOBARBITAL; PHENOTHIAZINE DERIVATIVE; PROPOFOL; PSYCHOTROPIC AGENT;

ANTICHOLINERGIC EFFECT; BODY BUILDING; CATALEPSY; CONFERENCE PAPER; DETOXIFICATION; DRUG ABUSE; DYSTONIA; EUPHORIA; HEART ARRHYTHMIA; HUMAN; NARCOLEPSY; PSYCHOSIS; QT PROLONGATION; SEIZURE SUSCEPTIBILITY; WITHDRAWAL SYNDROME; ADDICTION; PATHOPHYSIOLOGY; REVIEW;

4-BUTYROLACTONE; HUMANS; SODIUM OXYBATE; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 14544296341     PISSN: 11762551     EISSN: None     Source Type: Journal    
DOI: 10.2165/00139709-200423010-00005     Document Type: Conference Paper

References (37)

1. Smith KM, Larive LA, Romanelli F. Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate. Am J Health Syst Pharm 2002; 56: 1067-76
2. Placement of gamma-butyrolactone in List I of the Controlled Substances Act (21 U. S.C. 802(34)). Drug Enforcement Administration, Justice. Final rule. Fed Regist 2000 Apr 24; 65 (79): 21645-7
3. Drug Abuse Warning Network. The DAWN report [online]. Available from URL: http://www.samsha.gov/oas/dawn.htm [Accessed 2004 Feb 29]
4. Takahara J, Yunoki S, Yakushiji W, et al. Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactin release in humans. J Clin Endocrinol Metab 1977; 44 (5): 1014-7
5. Van Cauter E, Plat L, Scharf MB, et al. Simultaneous stimulation of slow-wave sleep and growth hormone secretion by gamma-hydroxybutyrate in normal young men. J Clin Invest 1997; 100 (3): 745-53
6. Gallimberti L, Canton G, Gentile N, et al. Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome. Lancet 1989; II: 787-9
7. Gallimberti L, Ferri M, Ferrara SD, et al. Gamma-hydroxybutyric acid in the treatment of alcohol dependence: a double-blind study. Alcohol Clin Exp Res 1992; 16: 673-6
8. US Xyrem® Multi-Center Study Group. The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not produce withdrawal symptoms. J Toxicol Clin Toxicol 2003; 41 (5): 131-5
9. Glisson JK, Norton J. Self-medication with γ-hydroxybutyrate to reduce alcohol intake. South Med J 2002; 95 (8): 926-8
10. Vickers M. Gamma-hydroxybutyric acid. Int Anesthesiol Clin 1969; 7: 75-9
11. Dyer JE, Roth B, Hyma BA. Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med 2001; 37: 147-53
12. Rambourg-Schepens MO, Buffet M, Durak C, et al. Gamma-butyrolactone poisoning and its similarities to gamma-hydroxybutyric acid: two case reports. Vet Hum Toxicol 1997; 39: 234-5
13. Snead OC, Furner R, Liu CC. In vivo conversion of gamma-aminobutyric acid in rat brain: studies using stable isotopes. Biochem Pharmacol 1989; 38: 4375-80
14. Ferrara SD, Zoti S, Tedeschi L, et al. Pharmacokinetics of gamma-hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses. Br J Clin Pharmacol 1992; 34: 231-5
15. Wong CGT, Gibson MK, Snead CO. From the street to the brain: neurobiology of the recreational drug γ-hydroxybutyric acid. Trends Pharmacol Sci 2004; 25 (1): 29-34
16. Maitre M. The γ-hydroxybutyrate signaling system in brain: organization and functional implications. Prog Neurobiol 1997; 51: 337-61
17. A receptor complex in the rat cerebral cortex. Psychopharmacology 1991; 104: 351-5
18. Xie X, Smart TG. Gamma-hydroxybutyrate hyperpolarizes hippocampal neurons by activating GABA B receptors. Eur J Pharmacol 1992; 212: 291-4
19. Schmidt-Mutter C, Muller C, Zwiller J, et al. Gobaille S. Gamma-hydroxybutyrate and cocaine administration increases mRNA expression of dopamine D1 and D2 receptors in rat brain. Neuropsychopharmacology 1999; 21 (5): 662-9
20. Hechler V, Gobaille S, Maitre M. Selective distribution pattern of gamma-hydroxybutyrate receptors in the rat forebrain and midbrain as revealed by quantitative autoradiography. Brain Res 1992; 572: 345-8
21. Rumigny J, Maitre M, Cash C, et al. Regional and subcellular localization in the rat brain of the enzymes that can synthesize gamma-hydroxybutyric acid. J Neurochem 1981; 36: 1433-8
22. +-dependent uptake sysiiem for gamma-hydroxybutyrate in membrane vesicles prepared from rat brain. J Neurochem 1982; 38: 1570-5
23. Bania TC, Ashar T, Press G, et al. Gamma-hydroxybutyric acid tolerance and withdrawal in a rat model. Acad Emerg Med 2003; 10 (7): 697-704
24. van Sassenbroeck D, De Paepe P, Belpaire F, et al. Tolerance to gamma-hydroxybutyrate in the rat: pharmacokinetic and pharmacodynamic aspects. Acad Emerg Med 2002; 9: 484-5
25. Mycyk MB, Wilemon C, Aks SE. Two cases of withdrawal from 1,4-butanediol use. Ann Emerg Med 2001; 38 (3): 345-6
26. Mamelak M. Gamma-hydroxybutyrate: an endogenous regulator of energy metabolism. Neurosci Biobehav Rev 1989; 13: 187-98
27. Miotto K, Darakjian J, Basch J, et al. Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal. Am J Addict 2001; 10 (3): 232-41
28. Rosenberg MH, Deerfield LJ, Baruch EM. Two cases of severe gamma-hydroxybutyrate withdrawal delirium on a psychiatric unit: recommendations for Management. Am J Drug Alcohol Abuse 2003; 29 (2): 487-96
29. Galloway GP, Frederick SL, Staggers Jr FE, et al. Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction 1997; 92 (1): 89-96
30. Sivilotti MAL. Burns MJ, Aaron CK, et al. Pentobarbital for severe gamma-butyrolactone withdrawal. Ann Emerg Med 2001; 38 (6): 660-5
31. Sharma AN, Nelson L, Hoffman RS. Severe gamma-butyrolactone withdrawal [abstract]. J Toxicol Clin Toxicol 2000; 38: 535
32. Greene T, Dougherty T, Rodi A. Gamma-butyrolactone (GBL) withdrawal presenting is acute psychosis [abstract]. J Toxicol Clin Toxicol 1999; 37: 651
33. Hoes MJ, Vree TB, Guelen PJ. Gamma-hydroxybutyric acid as hypnotic: clinical and pharmacokinetic evaluation of gamma-hydroxybutyric acid as hypnotic in man. Encephale 1980; 6: 93-9
34. Saitz R, Mayo-Smith MF, Roberts MS, et al. Individualized treatment for alcohol withdrawal: a randomized double-blind controlled trial. JAMA 1994; 272: 519-23
35. Craig K, Gomez H, McManus J, et al. Severe gamma-hydroxybutyrate withdrawal: a case report and literature review. J Emerg Med 2000; 18: 65-70
36. Berton F, Brancucci A, Beghe F, et al. Gamma-hydroxybutyrate inhibits excitatory postsynaptic potentials in rat hippocampal slices. Eur J Pharmacol 1999; 380 (2-3): 109-16
37. Blum K, Eubanks JD, Wallace JE, et al. Enhancement of alcohol withdrawal convulsions in mice by haloperidol. Clin Toxicol 1976; 9: 427-34